Corvus Pharmaceuticals, Inc. (CRVS)
Nasdaq · Healthcare · Biotechnology
$10.74−1.47%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $904M
- 52-week range
- $6.39 – $26.95
- 52-week change
- +58.66%
- EPS (trailing)
- −$0.62
- Analyst rating
- 1.1 Strong buy
- Next earnings
- Nov 3, 2026
Fiscal year to Dec 2025
- Net income
- −$15.3M
- Diluted EPS
- −$0.53
- Free cash flow
- −$33.0M
From the company’s annual report on SEC EDGAR.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer.
Headquarters: South San Francisco, United States · 37 employees · corvuspharma.com